At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,349 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Xeljanz Access Barriers Via Patient OOP Costs and TNFi Cycling
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 1,349 participants across 1 site.
Detailed Summary
This is a retrospective cohort study to evaluate patient characteristics, treatment patterns including a 6-factor effectiveness proxy measure, health care resource use and associated costs among Rheumatoid Arthritis patients initiating treatment comparator groups of interest between January 2014 and September 2016 across three United States insurance claims databases.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedAug 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedAug 6, 2019
Enrollment StartMay 20, 2019
Primary CompletionOct 21, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.9 years ago